Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04514419 | Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel | active not recruiting | Phase 3 | 408 | BioRay Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 21, 2025 | clinicaltrials |
| NCT03731845 | Evaluation of Individual Sensitivity to the Gonadotoxicity of Chemotherapy in Young Patients With Breast Cancer(ESIGON) | active not recruiting | N/A | 73 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Nov 20, 2025 |
| clinicaltrials |
| NCT06328738 | ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer | active not recruiting | Phase 1 | 275 | Enliven TherapeuticsINDUSTRY | 7 | Nov 19, 2025 | clinicaltrials |
| NCT04042701 | DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer | active not recruiting | Phase 1 | 115 | Daiichi SankyoINDUSTRY | 4 | Nov 18, 2025 | clinicaltrials |
| NCT04425018 | MARGetuximab Or Trastuzumab (MARGOT)(MARGOT) | active not recruiting | Phase 2 | 174 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT04180371 | Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | active not recruiting | Phase 1 / Phase 2 | 288 | BicycleTx LimitedINDUSTRY | 5 | Nov 17, 2025 | clinicaltrials |
| NCT06735742 | A Study to Learn About the Safety of TALZENNA for the Treatment of Breast Cancer | active not recruiting | — | 3 | PfizerINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT01093612 | Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer | active not recruiting | N/A | 18 | City of Hope Medical CenterOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT02827877 | Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer | active not recruiting | Phase 2 | 18 | City of Hope Medical CenterOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT04561362 | Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | active not recruiting | Phase 1 / Phase 2 | 329 | BicycleTx LimitedINDUSTRY | 6 | Nov 14, 2025 | clinicaltrials |
| NCT05949021 | OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer | active not recruiting | Phase 2 | 30 | Mridula George, MDOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT05912231 | Ultrahypofractionation and Normal Tissue Toxicity | active not recruiting | N/A | 60 | Massachusetts General HospitalOTHER | 1 | Nov 13, 2025 | clinicaltrials |
| NCT01153035 | Excision Followed by Radiofrequency Ablation for Breast Cancer(ABLATE) | active not recruiting | N/A | 104 | University of ArkansasOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT01230346 | Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer | active not recruiting | N/A | 493 | City of Hope Medical CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT01472094 | The Hurria Older PatiEnts (HOPE) With Breast Cancer Study | active not recruiting | — | 700 | City of Hope Medical CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT00572481 | Axillary Reverse Mapping(ARM) | active not recruiting | Phase 2 | 1,000 | University of ArkansasOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT02603341 | Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial | active not recruiting | N/A | 1,238 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT05078190 | Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer(CCT2) | active not recruiting | — | 200 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT00996710 | Genomic Structural Variation in Cancer Susceptibility | active not recruiting | — | 1,275 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT03707340 | A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase Inhibitors | active not recruiting | Phase 2 | 43 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT04821141 | Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens | active not recruiting | Phase 2 | 120 | University of Kansas Medical CenterOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT03589339 | NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy | active not recruiting | Phase 1 | 145 | NanobiotixINDUSTRY | 1 | Oct 24, 2025 | clinicaltrials |
| NCT06260332 | Physical Activity Intervention for the Improvement of Pain in Young, Hispanic Breast Cancer Survivors | active not recruiting | N/A | 25 | New Mexico Cancer Research AllianceOTHER | 1 | Oct 23, 2025 | clinicaltrials |
| NCT03529110 | DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03] | active not recruiting | Phase 3 | 524 | Daiichi SankyoINDUSTRY | 15 | Oct 21, 2025 | clinicaltrials |
| NCT06265428 | A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer | active not recruiting | Phase 3 | 228 | DualityBio Inc.INDUSTRY | 1 | Oct 20, 2025 | clinicaltrials |
| NCT05565417 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | active not recruiting | Phase 1 / Phase 2 | 67 | Immunitas TherapeuticsINDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT03289195 | Evaluate The Accuracy Of Breast MRI Biopsy In Diagnosing A Complete Tumor Response For Some Women Following Neoadjuvant Chemotherapy For Breast Cancer | active not recruiting | N/A | 31 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT02783664 | Evaluating the Effects of Genetic Testing on Patients' Stress Levels | active not recruiting | — | 164 | Medical College of WisconsinOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT04009044 | Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast | active not recruiting | Phase 2 | 156 | Northwestern UniversityOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT01203839 | Partial Breast Irradiation (PBI) Using 40 Gy for Select Patients With Early Invasive or Noninvasive Breast Cancer | active not recruiting | Phase 2 | 110 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT02393794 | Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) | active not recruiting | Phase 1 / Phase 2 | 51 | Priyanka SharmaOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT05840211 | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy(ASCENT-07) | active not recruiting | Phase 3 | 654 | Gilead SciencesINDUSTRY | 28 | Oct 3, 2025 | clinicaltrials |
| NCT00989638 | A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer | active not recruiting | — | 305 | University of ChicagoOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT02826434 | Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer | active not recruiting | Phase 1 | 22 | Massachusetts General HospitalOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT07201389 | CARE (Chemotherapy Alopecia REduction)(CARE) | active not recruiting | N/A | 30 | George Washington UniversityOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT05036252 | Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity | active not recruiting | — | 23 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT05654532 | Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer | active not recruiting | Phase 1 | 100 | Accutar Biotechnology IncINDUSTRY | 1 | Sep 30, 2025 | clinicaltrials |
| NCT03581136 | Phase II Multi-center Trial Evaluating 5 Fraction Stereotactic Partial Breast Irradiation Using Gammapod | active not recruiting | N/A | 74 | University of Texas Southwestern Medical CenterOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT05160545 | A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer | active not recruiting | Phase 1 | 36 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05339685 | A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors | active not recruiting | Phase 1 | 82 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT02562118 | Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 40 | National University Hospital, SingaporeOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT04520269 | A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR) | active not recruiting | Phase 1 / Phase 2 | 74 | National University Hospital, SingaporeOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT04280536 | Phase II Study of FTD/TPI (Lonsurf) in Metastatic Breast Cancers With or Without Prior Exposure to Fluoropyrimidines (LONBRECA) | active not recruiting | Phase 1 / Phase 2 | 86 | National University Hospital, SingaporeOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT07185334 | Single-Stage Prepectoral Placement of Textured Implants Using a Polyester Mesh Endoprostheses With Fluoropolymer Coating in Patients With Breast Cancer(FluoropolyMesh) | active not recruiting | N/A | 100 | Saint Petersburg State University, RussiaOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT03820063 | Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study(TRAIN-3) | active not recruiting | Phase 2 | 462 | Borstkanker Onderzoek GroepNETWORK | 1 | Sep 19, 2025 | clinicaltrials |
| NCT04763915 | Improving Care After Inherited Cancer Testing(IMPACT) | active not recruiting | N/A | 720 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT02889874 | EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer(EXPERT) | active not recruiting | N/A | 1,167 | Breast Cancer Trials, Australia and New ZealandOTHER | 9 | Sep 18, 2025 | clinicaltrials |
| NCT05382286 | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer(ASCENT-04) | active not recruiting | Phase 3 | 443 | Gilead SciencesINDUSTRY | 28 | Sep 18, 2025 | clinicaltrials |
| NCT04088708 | Gut Microbe Composition, Exercise, and Breast Breast Cancer Survivors(ROME) | active not recruiting | N/A | 126 | University of Alabama at BirminghamOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT05871008 | Integrated Actionable Aging Assessment for Cancer Patients Pilot | active not recruiting | N/A | 35 | University of Colorado, DenverOTHER | 1 | Sep 15, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Nov 21, 2025source: clinicaltrials